SEC Form 4
Lineage Cell Therapeutics, Inc. (LCTX) insider trading
In the 12 months to Nov 19, 2026, 2 LCTX insiders reported open-market purchases of $81.5K across 3 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $81.5K
- 3 filings
Who traded LCTX, and when
- Purchase
LCTX daily close from Nov 19, 2025 to Nov 18, 2026, between $0.80 and $1.96, last $0.84. 0 sale and 3 purchase filings by 2 insiders, marked at their filing dates. Brian M. Culley, President and CEO: bought $61.5K across 2 filings, first filed Mar 12, 2026, last Nov 17, 2026. Deborah J. Andrews, Director: bought $20.0K across 1 filing, first filed Nov 17, 2026, last Nov 17, 2026.
Largest mark · tap a row for others
Brian M. Culley · President and CEO
Purchase $37,098
40,500 shares at $0.92 avg
Filed Nov 17, 2026 · traded Nov 16
Close on filing date $0.82
Brian M. Culley · President and CEO
President and CEO
$61.5K boughtDeborah J. Andrews · Director
Director
$20.0K boughtOpen-market trades
3 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Brian M. Culley | President and CEO | — | $61.5K | 2 | — | |
| Deborah J. Andrews | Director | — | $20.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Brian M. Culley President and CEO | Purchase | 40,500 | $0.92 | $37.1K | 296,016 | |
traded | Deborah J. Andrews Director | Purchase | 25,000 | $0.80 | $20.0K | 40,578 | |
traded | Brian M. Culley President and CEO | Purchase | 15,000 | $1.63 | $24.4K | 255,516 |
GET /stocks/filings/vX/form-4?tickers=LCTX&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"LCTX"
],
"issuer_cik": "0000876343",
"owner_cik": "0001310683",
"accession_number": "0001193125-26-464849",
"form_type": "4",
"filing_date": "2026-11-17",
"period_of_report": "2026-11-16",
"issuer_name": "Lineage Cell Therapeutics, Inc.",
"issuer_trading_symbol": "LCTX",
"owner_name": "Culley Brian M",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-16",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 40500,
"transaction_price_per_share": 0.916,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 296016,
"transaction_value": 37098,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $1.00 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1."
}
]
},
{
"tickers": [
"LCTX"
],
"issuer_cik": "0000876343",
"owner_cik": "0001325697",
"accession_number": "0001193125-26-465809",
"form_type": "4",
"filing_date": "2026-11-17",
"period_of_report": "2026-11-16",
"issuer_name": "Lineage Cell Therapeutics, Inc.",
"issuer_trading_symbol": "LCTX",
"owner_name": "ANDREWS DEBORAH J",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-16",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 25000,
"transaction_price_per_share": 0.8,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 40578,
"transaction_value": 20000,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 8 records
- Option exercises2 records
- Tax withholding4 records
- Grants and awards2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Lineage Cell Therapeutics, Inc.'s CEO sold stock?
No. Brian M. Culley (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is LCTX’s insider data?
These are LCTX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track LCTX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for LCTX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.